Patent ID: 8652787

Claim:
A method of selecting a subject diagnosed with melanoma as a candidate for treatment with an ERBB4 inhibitor, a PI3K/AKT pathway inhibitor, or both, comprising: (a) detecting the presence or absence of a mutation in the ERBB4 gene in a melanoma sample from the subject, wherein the mutation is selected from G949A, G1354A, G1624A, C1630T, G1687A, G2506A and G2614A (numbered with reference to SEQ ID NO: 1), and wherein the presence of the mutation in the ERBB4 gene indicates that the subject is a candidate for treatment with an ERBB4 inhibitor, a PI3K/AKT pathway inhibitor, or both; and (b) administering to the subject an ERBB4 inhibitor, a PI3K/AKT pathway inhibitor, or both when the mutation in the ERBB4 gene is present in the sample from the subject.